Including elevated remnant cholesterol in risk assessment for atherosclerotic cardiovascular disease (ASCVD) may better indicate patients who are likely to have a CV event than current models,1,2 and help to guide future treatment strategies.
Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses growing evidence supporting the use of remnant cholesterol measurement in both primary and secondary prevention settings.
